Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients

Li, 2011, A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China, BMC Cancer, 11, 364, 10.1186/1471-2407-11-364 Song, 2014, Age of diagnosis of breast cancer in China: almost 10 years earlier than in the United States and the European union, Asian Pac J Cancer Prev, 15, 10021, 10.7314/APJCP.2014.15.22.10021 Yao, 2009, Breast cancer in women younger than 25: clinicopathological features and prognostic factors, Ann Oncol, 20, 387, 10.1093/annonc/mdn711 Azim, 2012, Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling, Clin Cancer Res, 18, 1341, 10.1158/1078-0432.CCR-11-2599 Collins, 2012, Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer, Breast Cancer Res Treat, 131, 1061, 10.1007/s10549-011-1872-9 Keegan, 2012, Occurrence of breast cancer subtypes in adolescent and young adult women, Breast Cancer Res, 14, R55, 10.1186/bcr3156 Partridge, 2012, The effect of age on delay in diagnosis and stage of breast cancer, Oncologist, 17, 775, 10.1634/theoncologist.2011-0469 Partridge, 2016, Subtype-dependent relationship between young age at diagnosis and breast cancer survival, J Clin Oncol, 34, 3308, 10.1200/JCO.2015.65.8013 Li, 2018, Integrative clinical genomics of early-onset breast cancer, J Clin Oncol, 36 Sun, 2017, Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients, Clin Cancer Res, 23, 6113, 10.1158/1078-0432.CCR-16-3227 Yang, 2015, Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing, PLoS One, 10, 10.1371/journal.pone.0125571 2017, Chinese expert consensus on BRCA data interpretation, Chin J Pathol, 46, 293 Gerstl, 2018, Pregnancy outcomes after a breast cancer diagnosis: a systematic review and meta-analysis, Clin Breast Cancer, 18, e79, 10.1016/j.clbc.2017.06.016 Rosen, 2009, Psychosocial distress in young cancer survivors, Semin Oncol Nurs, 25, 268, 10.1016/j.soncn.2009.08.004 Paluch-Shimon, 2017, ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3), Breast, 35, 203, 10.1016/j.breast.2017.07.017 Oktay, 2018, Fertility preservation in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol, 36, 1994, 10.1200/JCO.2018.78.1914 Yasmin, 2018, Fertility preservation for medical reasons in girls and women: british fertility society policy and practice guideline, Hum Fertil (Camb Engl), 21, 3, 10.1080/14647273.2017.1422297 Ye, 2015, Equivalent survival with mastectomy or breast-conserving surgery plus radiation in young women aged < 40 years with early-stage breast cancer: a national registry-based stage-by-stage comparison, Clin Breast Cancer, 15, 390, 10.1016/j.clbc.2015.03.012 Cao, 2014, Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-year outcomes in a population-based cohort, Int J Radiat Oncol Biol Phys, 90, 509, 10.1016/j.ijrobp.2014.06.041 Lagendijk, 2018, Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients, Int J Cancer, 142, 165, 10.1002/ijc.31034 2017, China Anticancer Association guidelines and norms for the diagnosis and treatment of breast Cancer (2017 edition), China Oncol, 27, 695 Botteri, 2010, Analysis of local and regional recurrences in breast cancer after conservative surgery, Ann Oncol, 21, 723, 10.1093/annonc/mdp386 Litière, 2012, Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial, Lancet Oncol, 13, 412, 10.1016/S1470-2045(12)70042-6 Lowery, 2012, Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype, Breast Cancer Res Treat, 133, 831, 10.1007/s10549-011-1891-6 Pierce, 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer, J Clin Oncol, 24, 2437, 10.1200/JCO.2005.02.7888 Krag, 2010, Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 11, 927, 10.1016/S1470-2045(10)70207-2 Carter, 2016, Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction, Ann Surg Oncol, 23, 3190, 10.1245/s10434-016-5407-9 De La Cruz, 2016, Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review, Ann Surg Oncol, 23, 3247, 10.1245/s10434-016-5313-1 Huang, 2018, Oncological safety of nipple-sparing mastectomy in young patients with breast cancer compared with conventional mastectomy, Oncol Lett, 15, 4813 Metcalfe, 2004, Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol, 22, 2328, 10.1200/JCO.2004.04.033 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 van Sprundel, 2005, Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers, Br J Cancer, 93, 287, 10.1038/sj.bjc.6602703 McDonnell, 2001, Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer, J Clin Oncol, 19, 3938, 10.1200/JCO.2001.19.19.3938 Kummerow, 2015, Nationwide trends in mastectomy for early-stage breast cancer, JAMA Surg, 150, 9, 10.1001/jamasurg.2014.2895 Lambertini, 2017, Ovarian function suppression in premenopausal women with early-stage breast cancer, Curr Treat Opt Oncol, 18, 4, 10.1007/s11864-017-0442-8 Lambertini, 2015, Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies, Ann Oncol, 26, 2408, 10.1093/annonc/mdv374 Azim, 2013, Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study, J Clin Oncol, 31, 73, 10.1200/JCO.2012.44.2285 Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379 Yeo, 2019, Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression, Breast Cancer Res Treat, 177, 549, 10.1007/s10549-019-05318-5 Regan, 2016, Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials, J Clin Oncol, 34, 2221, 10.1200/JCO.2015.64.3171 Davies, 2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016/S0140-6736(11)60993-8 Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1 Gray, 2013, aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer, J Clin Oncol, 31, 10.1200/jco.2013.31.18_suppl.5 McDonald Wade, 2008, Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings, Oncology, 75, 192, 10.1159/000163059 Regan, 2013, Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials, Breast, 22, 1094, 10.1016/j.breast.2013.08.009 Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037 Lambertini, 2015, Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial, JAMA, 314, 2632, 10.1001/jama.2015.17291 Kaufmann, 2003, Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer, Eur J Cancer, 39, 1711, 10.1016/S0959-8049(03)00392-7 Karlsson, 2011, Long-term results of international breast cancer study group trial VIII: adjuvant chemotherapy plus Goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer, Ann Oncol, 22, 2216, 10.1093/annonc/mdq735 Gnant, 2011, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial, Lancet Oncol, 12, 631, 10.1016/S1470-2045(11)70122-X Kim, 2016, The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress, BMC Cancer, 16, 319, 10.1186/s12885-016-2354-6 Burstein, 2016, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression, J Clin Oncol, 34, 1689, 10.1200/JCO.2015.65.9573 Sehdev, 2009, Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer, Curr Oncol (Toronto, Ont), 16, S14, 10.3747/co.v16i0.457 Verma, 2011, Patient adherence to aromatase inhibitor treatment in the adjuvant setting, Curr Oncol (Toronto, Ont), 18, S3, 10.3747/co.v18i0.899 Bernhard, 2015, Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials, Lancet Oncol, 16, 848, 10.1016/S1470-2045(15)00049-2 Lee, 2010, Value of early referral to fertility preservation in young women with breast cancer, J Clin Oncol, 28, 4683, 10.1200/JCO.2010.30.5748 Azim, 2013, Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study, J Clin Oncol, 31, 73, 10.1200/JCO.2012.44.2285 2004, Ethical principles of human assisted reproductive technology and human sperm bank, Chin J Reprod Health, 15, 72 Lu, 2017, Ethical issues of oocyte cryopreservation, J Reprod Med, 26, 224 2004, Technical specification for human assisted reproductive technology, Chin J Reprod Health, 15, 4 Hourvitz, 2015, Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield, Reprod Biomed Online, 31, 497, 10.1016/j.rbmo.2015.06.025 Meirow, 2016, Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria, Fertil Steril, 106, 467, 10.1016/j.fertnstert.2016.04.031 Rodriguez-Wallberg, 2012, Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer, Oncologist, 17, 1409, 10.1634/theoncologist.2012-0236 Kim, 2016, Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer, J Clin Endocrinol Metab, 101, 1364, 10.1210/jc.2015-3878 Oktay, 2006, Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy, J Clin Endocrinol Metab, 91, 3885, 10.1210/jc.2006-0962 Azim, 2008, Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study, J Clin Oncol, 26, 2630, 10.1200/JCO.2007.14.8700 Meirow, 2014, Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies, Fertil Steril, 102, 488, 10.1016/j.fertnstert.2014.05.017 Oktay, 2005, Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation, J Clin Oncol, 23, 4347, 10.1200/JCO.2005.05.037